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Although methotrexate is widely used in clinical practice there remains signiﬁcant lack of understanding of its mechanisms of
action and the factors that contribute to the variability in toxicity and response seen clinically. In addition to diﬀerences in drug
administration, factors that aﬀect pharmacokinetics and pharmacodynamics such as genetic variation may explain individual
diﬀerencesindrugbiotransformation.However,thepediatricpopulationhasanadditionalfactortoconsider,namelytheontogeny
of gene expression which may result in variation throughout growth and development. We review the current understanding of
methotrexate biotransformation and the concept of ontogeny, with further discussion of how to implement a developmental
pharmacogenomics approach in future studies.
1.Introduction
Methotrexate (MTX) is the most common second-line ther-
apeutic agent used to treat Juvenile Idiopathic Arthritis (JIA)
worldwide.Regardlessofageordiseasesubtype,considerable
interindividual variability in clinical response and adverse
reactions exists with MTX, and thus far, there have been
no predictive variables for outcomes in patients taking this
medication. Since the onset of clinical response may take
months to manifest, the risk to beneﬁt ratio early in treat-
ment is altered, as there is risk for toxicity for several weeks
to months before knowing if the medication has resulted
in a clinical beneﬁt. Side eﬀects may compromise eﬃcacy
due to patient noncompliance, clinician dose adjustment,
or discontinuation even if the drug eventually is medically
eﬀective. Medication dose alteration or discontinuation in
thefaceofactivediseaseisunacceptablewhenthealternatives
for therapy in childhood arthritis are few and poorly studied
in this population. By utilizing pharmacogenomic principles
and a personalized therapeutic strategy, we hope to improve
eﬃcacyandpreventadversedrugreactionsinchildrentaking
MTX to treat JIA.
2.Developmental Pharmacogenetics
When exploring the variability in response and toxicity to
any medication used in children, a concept often overlooked
is ontogeny [1]. The eﬀects of development can be applied
at every level of drug disposition and response. These
eﬀects range from diﬀerences in gastric pH [2, 3]a n d
gastricemptying[4]whic hma yaﬀectabsorption, tochanges
in circulating plasma proteins with age that may aﬀect
drug distribution [5]. Developmental changes in phase I
drug biotransformation and phase II conjugating enzyme
expression have the potential to alter drug metabolism
[6], and developmental diﬀerences in glomerular ﬁltration
rates [7]w i l la ﬀect drug excretion in children compared
to adults. Common drug biotransformation pathways are
also shared with endogenous compounds involved in growth
and development, such as testosterone, cortisol, and vitamin
D3 [8], so it is not surprising that some of these pathways
may be aﬀected by the rapid growth and maturation of the
pediatric patient, for example, during infancy and puberty.
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rates or trajectories may also lead to variability in drug
disposition and response.
Although pharmacogenetics appropriately strives to
identify the correct dose of the correct drug for the correct
person, the impact of development on an individual’s
response to a drug must be taken into account [1]. Geno-
typing an individual for variations that aﬀect function is
an important step to understanding variability in outcomes;
however, knowing if and when that gene is expressed
is a concept important to fully understanding genotype-
phenotype relationships in children [9, 10]. An approach
to investigating hypotheses related to drug outcomes in
children can be guided by the following questions [9].
(1) What gene products are quantitatively impor-
tant in the disposition (absorption, distribution,
metabolism, and excretion) of the drug in question?
(2) For each gene product, what is the developmental
trajectory for the acquisition of functional activity?
(3) Is allelic variation in the gene(s) of interest associated
with any functional consequences in vivo?
(4) Is there any evidence that allelic variation aﬀects
the developmental trajectory of the drug disposition
phenotype?
(5) What is the developmental context in which the
gene(s) of interest is/are operating?
This process is also relevant for genes/gene products
involved in drug response. Partnered with the understand-
ing of genetic variation in an individual, appreciating
the changes in gene expression throughout growth and
development will allow us to manage the complexity of
therapeutics in children. We strive to individualize therapy
for children rather than extrapolate from adult experience,
which traditionally has been the norm.
3. JIA Background
Juvenile Idiopathic Arthritis (JIA), formerly termed Juvenile
Chronic Arthritis (JCA) or Juvenile Rheumatoid Arthritis
(JRA) is one of the most common chronic diseases of
childhood, and is an important cause of morbidity and
disability in children. It aﬀects an estimated 300,000 children
in the United States. This disease is characterized by idio-
pathic peripheral arthritis with an immunoinﬂammatory
pathogenesis, thought to be triggered by an external antigen
[11]. There is also speculation of a genetic predisposition
for the disease [12–15]. JIA has a heterogeneous phenotypic
expression, and includes several disease subtypes, whose
classiﬁcation continues to be revised and validated by
clinicians worldwide [15].
Despite diﬀerences in disease expression between adults
and children, like in many pediatric diseases, children are
treated with generally the same armamentarium of drugs
used to treat RA in adults. With the advent of Disease
ModifyingAntirheumaticDrugs(DMARDs),thephilosophy
oftreatmentchangedfromsimplepaincontroltoprevention
oferosionsandlong-termdamageofthejoints.Methotrexate
(MTX), a folic acid antagonist, was approved by the Food
and Drug Administration for the treatment of RA in 1988,
and several uncontrolled descriptive studies suggested, and
a randomized placebo-controlled double blind clinical trial
demonstrated the eﬀectiveness of MTX in children with
JIA [16–21]. MTX has subsequently become the most
common second-line therapeutic agent used to treat Juvenile
Idiopathic Arthritis (JIA) worldwide.
Although the collective clinical experience with MTX
has been vast, there are still unanswered questions about
its mechanism of action, and considerable interindividual
variability in clinical response and adverse reactions exists
[22–24]. Thus far, there have been few predictors for eﬃcacy
or toxicity in pediatric patients taking this medication,
and clinicians essentially dose by trial and error. Factors
that could contribute to this variability are extensive, and
some are unique to the pediatric population. We would
like to explore the potential sources of variability that may
contribute to outcomes on MTX in JIA.
4. CellularEffects of MTX
Methotrexate, a folic acid analog and potent inhibitor of
several enzymes within the folate pathway, has been used in
low doses for the treatment of rheumatic disease over the last
several decades. For rheumatic conditions, the dose range
in pediatrics spans 10-fold, ranging from 0.1mg/kg/dose
to 1mg/kg/dose, administered on a weekly basis. Options
include oral and subcutaneous administration, but intra-
muscular and intravenous administration are possible,
although less practical in the outpatient setting. Before being
taken into the body, contributors to variability that cannot
be overlooked include patient compliance, diﬀerences in
administered dose, and route of administration. Children,
who are a fraction of the weight of their adult counterparts,
are dosed with the same absolute MTX dose, despite their
smaller size. Although attention has been brought to this
phenomenon, there continues to be little understanding of
why children appear to require, relative to body weight,
higher doses of MTX or how these doses are tolerated.
Serum MTX concentrations have not been found useful to
predict response or toxicity with little correlation with dose
or outcome [25–27].
MTX has been best studied at the cellular level. It is
knownthatMTXactsasafolateantagonist,enteringthecells
primarily through the reduced folate carrier (RFC/SLC19A1)
[28]. Once intracellular, MTX is bioactivated to a polyglu-
tamated form by folylpolyglutamyl synthase (FPGS), which
enhances the pharmacological activity and intracellular
retention of MTX [29]. In the RA and pediatric oncology
literature, current evidence indicates that the enzymatic
addition of glutamate residues to the MTX molecule in vivo
(polyglutamation/MTXglun) is critical for pharmacologic
activity by increasing the intracellular concentration of the
drug and increasing its aﬃnity for its therapeutic targets,
thereby allowing more opportunity for its inhibitory eﬀects
to be exerted upon its target enzymes [29–31]. The initial
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(DHFR), which forms tetrahydrofolate, a precursor required
for one carbon donation for synthesis of thymidylate,
purines, methionine and serine, remethylation of homocys-
teine to form methionine, and provision of methyl donors
for multiple methyltransferase enzymes [29]. Inhibition of
thymidylate synthetase (TYMS), both directly and indirectly
via depletion of tetrahydrofolate, leads to inhibition of
pyrimidine biosynthesis with a resultant antiproliferative
eﬀect [30]. The interruption of DNA synthesis was thought
to be the basis for rapidly dividing cell death in cancer
cells. Subsequently, the list of target genes has been extended
to include amino-imidazole carboxamide ribonucleotide
(AICAR) transformylase (gene name, ATIC), which inhibits
de novo purine synthesis and promotes the accumulation of
AICARribotide,inhibitingadenosinedeaminaseandleading
to a build up of adenosine, a potent anti-inﬂammatory
agent [32, 33]. Adenosine’s eﬀect is also mediated by
adenosine A2 receptors (ADORA2) ,w h i c ha r ep r e s e n to n
neutrophils, monocytes, lymphocytes and basophils, gener-
ally suppressing the immune function of these cells [32].
Gamma glutamyl hydrolase (GGH), the enzyme responsible
for glutamate removal from MTX, transforms MTX into a
form that can be eﬄuxed from the cell by the ATP-binding
cassette (ABC) family of transporters.
5. The Role of MethotrexatePolyglutamation
Due to the rapid decline in serum drug concentrations,
serum MTX concentrations are of limited utility in deter-
mining appropriate dosing or management of this medica-
tion [25–27]. On the other hand, RBC folate concentrations
are established during erythropoiesis and represent the
average folate status over the preceding 120 days [34].
By extension, MTX concentrations in RBCs represent a
reasonable surrogate biomarker of average drug exposure
over a similar period of time. In vitro studies have revealed
that the cellular response to folate deprivation is associated
with increased expression of FPGS and decreased expression
ofABCG2[35],suggestingthattheadaptivecellularresponse
to low folate involves increased polyglutamation to promote
the retention of folate. Homozygosity for the variant allele
of SLC19A1 (80A/A genotype) has been associated with
increasedconcentrationsofintracellularMTXglun compared
to heterozygous or WT genotypes in RA patients [33].
Although the data are limited, these examples reveal that
allelic variation in these genes resulting in increased or
decreased activity may be associated with inter-individual
variability in intracellular MTXglun.
Recent associations between MTXglun and clinical out-
comes have also been reported in the adult rheumatol-
ogy literature [33, 36, 37]. Higher levels of “long chain
MTXglun” (deﬁned in adults as MTXglu3 or greater, par-
ent MTX is MTXglu1) were associated with a number
of improved response measures in RA. The relationship
between MTXglun and side eﬀects of the medication has
not been established [38]. In children, experience is limited
to a single study reporting a total of 38 JIA patients,
and no relationship between intracellular total MTXglun
concentrationsandlikelihoodofresponsewasapparent[39].
As individual MTX polyglutamates diﬀer with respect to
their inhibitory eﬀects on target enzymes and inhibition is
modulated by folate polyglutamates [40], it is likely that
multiple as yet unidentiﬁed factors contribute to variability
in the relationship between MTXglun concentrations and
eﬃcacy and/or toxicity.
In order to better identify factors that may contribute
to the inconsistencies in response and toxicity to MTX, we
soughttocharacterizetheextentofvariabilityofintracellular
MTXglun concentrations in our JIA patient population, and
to investigate variables that may contribute to MTXglun
variability. We have measured intracellular MTXglun con-
centrations in a cohort of 104 JIA patients. In this cohort,
total intracellular MTXglun (MTXgluTOT,the sum of all
individual MTXglun) concentrations varied 40-fold with a
mean of 85.4 ± 48.8nmol/L. Concentrations of MTXglu1−7
were measured individually and as a percentage of each
patient’s MTXgluTOT.M T X g l u 3 was the most prominent
subtype identiﬁed, comprising 42% of MTXgluTOT,a n dw a s
most highly correlated with MTXgluTOT (r = 0.96) [41].
Route was a signiﬁcant predictor of MTXglu1−5 subtype.
Higher concentrations of MTXglu1+2 were observed in
patientsreceivingoraldosesofMTX,whereashigherconcen-
trations of MTXglu3−5 were observed in patients receiving
subcutaneousdosesofMTX(P <.0001),evenaftercorrecting
for dose. (Figure 1)[ 41]. These ﬁndings were also supported
further by hierarchical clustering, which revealed distinct
clusters of patients with higher proportions of MTXglu1+2
and a second cluster of patients in whom MTXglu3–5
predominated (Figure 2). After controlling for MTX dose,
subjects with higher proportions of MTXglu1+2 were more
likely to be receiving oral MTX (P<. 0001). Those with
higher proportions of MTXglu3−5 were more likely to be
receivingsubcutaneousMTX(P = .0097)[42].Inagreement
with Dolezalova and colleagues, we did not ﬁnd a strong
association of MTXglun concentrations (total or long chain)
with MTX response (unpublished data), but we are actively
investigating associations with clinical outcomes such as
GI toxicity and hepatic enzyme elevation. Our experience
demonstrates that MTXglun concentrations can be reliably
measured in children and are extensively variable [41], yet
the contributors to this variability are not fully explored.
6.MethotrexatePharmacogenetics and
ClinicalOutcomes
Several studies have investigated the association of folate
pathway pharmacogenetics and clinical outcomes with, at
times,conﬂictingresults.Ingenesassociatedwiththecellular
uptake and retention of MTX, there have been investi-
gations studying allelic variations in inﬂux transporters,
(RFC/SLC19A1),eﬄuxtransporters(ABCB1andABCC2),as
well as enzymes responsible for glutamation and deglutama-
tion, (GGH and FPGS). Previous investigations have found
no association between SNPs in RFC/SLC19A1 and clinical
outcomes in RA patients [43, 44]. Alternatively, upregulation
of the eﬄux transporter ABCG2 protein expression has been4 Human Genomics and Proteomics
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Figure 1: Comparison of MTXglun subgroups between oral (PO) and subcutaneous (SC) routes of administration. (a) Short chain
polyglutamates (MTXglu1+2) were more predominant with PO administration, and (b) higher concentrations of long chain polyglutamates
(MTXglu3−5) were more predominant with SC administration. Box and whisker plots are superimposed on data from individual patients.
Boxes include the median and interquartile range, and whiskers indicate the 10th and 90th percentiles.
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Figure 2:Hierarchical clusteringoftheproportionsofindividual MTXpolyglutamatesubtype(PG1−5%)orderedbytotalintracellular MTX
concentrations (MTXgluTOT) in 104 individual patients with JIA. Red denotes high concentrations, and green denotes low concentrations.
Proportions of short chain MTXglu1+2 (PG1% and PG2%) cluster together and proportions of long chain MTXglu3−5 (PG3%, PG4%,
PG5%) cluster together as subgroups. Each column represents an individual patient who has received MTX subcutaneously (black circles),
or orally (white circles) and has active arthritis (black circles), or inactive arthritis (red circles) at the time of the blood draw.
associated with MTX resistance in cancer cells [45], but
no associations with SNPs evaluated in FPGS and clinical
eﬀects of MTX have been observed [44]. On the other hand,
variations in GGH have shown conﬂicting associations with
toxicity, however, a potential association with MTX response
[33, 44].
Early work focused on genes directly involved in the
methionine remethylation cycle, speciﬁcally methylenete-
trahydrofolate reductase (MTHFR). Certain polymorphisms
in the MTHFR gene have been associated with greater
clinical improvement (MTHFR 1298AA and MTHFR 677CC
genotypes) while MTHFR 1298C and MTHFR 677T alleles
have been associated with an increased risk for toxicity
[43, 46, 47]. In a retrospective cohort study in JIA,
patients heterozygous for the MTHFR 677C/T genotype also
exhibited adverse eﬀects more frequently than homozygous
677C/C genotype [48], strengthening the adult associa-
tion. Additionally, 5-methyltetrahydrofolate homocysteine
methyltransferase (MTR) 2756GG was found to be over-
represented in pediatric osteosarcoma patients suﬀering GI
toxicity after being treated with high dose MTX [49], and it
has been associated with toxicity with low dose MTX in anHuman Genomics and Proteomics 5
a d u l tR Ac o h o r t[ 50], supporting the potential for a similar
eﬀect in children with JIA.
Genes within the adenosine pathway responsible for
de novo purine synthesis have begun to receive attention
from investigators following initial reports of the anti-
inﬂammatory eﬀects of the genes and enzymes within this
pathway.Favorableclinicalresponsehasbeenassociatedwith
polymorphisms in adenosine monophosphate deaminase
(AMPD1 34T allele), the ATIC 347CC genotype and inosine
triphosphate pyrophosphatase (ITPA 94CC) [51]. In a
recently reported JIA cohort, presence of allelic variation
in 2 ATIC SNPs (rs12995526 and rs4673990) and ITPA
(rs2295553) were associated with increased risk for lack
of response [52]. An increased risk of adverse eﬀects was
noted in ATIC 347G allele carriers [51]. Further work
investigating the adenosine receptor 2a gene (ADORA2a)
revealed several polymorphisms associated with GI toxicity
i na na d u l tR Ac o h o r t[ 53]. Polymorphisms in this pathway
carry the potential to eﬀect outcomes of arthritis patients
treated with MTX. However, available pediatric experience
suggeststhattheontogenyofgenesinthepurinebiosynthesis
and adenosine response pathways may warrant further
investigation.
Evaluation of the pyrimidine pathway has focused on
TYMS, primarily a tandem repeat sequence in the 5 -UTR
of the TYMS gene with enhancing function as well as a
6-bp deletion sequence in the 3 -UTR [54]. There have
been data suggesting individuals homozygous for 2 tandem
repeats had lower disease activity and better MTX response
than patients with a third repeat [33]. There have also been
data suggesting there is an association with the side eﬀect
of alopecia [55]. TYMS genetic variants have been also
used in combination with other genes including MTHFR,
ATIC, SLC191A, and SHMT to develop genomic indices,
in an attempt to take into account the complexities of
the cycle and gene-gene interactions that may contribute
to understanding drug response and toxicity [33, 38, 55].
This concept makes more clinical sense than a single SNP
approach, as a system as important as the folate cycle is likely
protected by redundancy and intricate feedback regulation
such that the function of this critically important pathway is
not subject to serious disruption by variation in single genes.
Thus far, there has been very little investigation into
genetic variation within the folate pathway in relation to
drug response in JIA. Being that this pathway is critical for
growth and development by contributing to the synthesis
of DNA precursors and regulation of gene expression
throughmethylationofcytosineandothermethyltransferase
reactions, it is likely that alterations in this pathway may have
functional consequence, and if ontogeny plays a role, there
may be more consequence during times of rapid growth and
development. Thus far, the ontogeny of the folate pathway
during postnatal growth and development has not been
investigated. Investigating this pathway will require a better
understanding of gene-gene interactions within the pathway,
as well as the baseline folate status and the cell’s response to
shifts in supply and demand during periods of active growth
and development as well as perturbation by a drug such as
MTX.
7. Systematc Approach to Address Methotrexate
Dispositionand Response inJIA
With extensive 40-fold variability in intracellular MTXglun
concentrations and distinct patterns of MTX polyglutama-
tion highly associated with route of drug administration,
one may consider absorption and cellular transport as key
contributors to this observed variability. Intestinal inﬂux
transporters include the solute carrier (SLC) transporters,
such as SLC19A1 (also known as the reduced folate carrier
(RFC)) and the proton coupled folate transporter/heme
carrier protein-1 (PCFT; SLC46A1) and folate receptors
(FRα,F R β,a n dF R γ)[ 56, 57]. The importance of these
transporters, speciﬁcally PCFT has been exempliﬁed by the
autosomal recessive disorder Hereditary Folate Malabsorp-
tion (HFM) where loss of function mutations in these
families have resulted in impaired folate absorption leading
to severe folate deﬁciency and impaired folate transport into
the CNS [57–59]. Further work has demonstrated that PCFT
also transports MTX, although less avidly than folate and has
demonstrated transporter inhibition by anionic compounds,
including sulfasalzine. In addition, proton-pump inhibitors
also inhibit PCFT transport function [59, 60], with the
potential for clinically important consequences given that
they often are coadministered with MTX in RA patients. In
mice fed a low folate diet, expression of these transporters in
the small intestine is increased [61], suggesting an adaptive
process.
Eﬄux transporters include the ATP-binding cassette
protein family of transporters (ABC transporters), which
transport either back into the lumen (ABCG2/BCRP,
ABCC2/MRP-2, ABCC4/MRP-4, and ABCB1/MDR1),
or through the basolateral membrane into the blood
(ABCC1/MRP-1, ABCC3/MRP-3, ABCC5/MPR-5) [56]. The
overlapping and compensatory functions of these eﬄux
transporters make investigation of their function complex.
GI toxicity has been reported in ABCC1/MRP1 (−/−) knock
out mice, found highly expressed in the small intestine[62].
In pediatric ALL patients, the presence of at least one variant
ABCC2-24 C>Tallele resulted in much higher MTX
A U Ci nf e m a l ep a t i e n t s[ 63]. Additionally, in RA patients,
increased MTX toxicity was noted in subjects carrying SNPs
in the ABCB1 and ABCC2 genes [64, 65] .V a r i a t i o ni nt h e
function of intestinal transporters, such as PCFT, may result
in diﬀerences in MTX bioavailability, and may play a part in
explainingwhychildren,whosebodysurfaceareaandweight
are much less than adults, still require a similar MTX dose
as adults to maintain an appropriate level of disease control.
The combination and relation of both inﬂux and eﬄux
transporter function will likely need to be better elucidated
before ﬁnal associations with genotype and phenotype can
be made.
After being absorbed from the gut, MTX is further
metabolized in the liver to its primary metabolite 7-OH-
MTX, and inﬂux and eﬄux transporters within the liver
can also be contributors to interpatient variability in
systemic availability and response to the drug, especially
when considering the inherent risk for hepatotoxicity.
The role of hepatic speciﬁc transporters such as Organic6 Human Genomics and Proteomics
Anion Transporter Polypeptides (OATP1B1/SLCO1B1,
OATP1B3/SLCO1B3) have received more attention with the
reported inﬂuence of the SLCO1B1∗5 haplotype (c.51T >
C) on statin pharmacokinetics and toxicity [66]. OATP1B1
is located at the sinusoidal membrane of hepatocytes, and
its transcript has been detected in hepatocytes [67]. It
has been shown to transport MTX in vitro [68], and in
pediatric patients with ALL, variations in OATP1B1 were
associated with clearance of MTX as well as GI toxicity [67].
Variations in the genotype of hepatic eﬄux transporters
such as ABCB1/MDR-1 and ABCC2/MRP-2 may also play
a role in drug response and toxicity. In ABCC2-deﬁcient
rats, MTX biliary excretion was signiﬁcantly reduced [69].
In ABCC2/ABCC3/ABCG2 (−/−)d e ﬁ c i e n tm i c e ,ad r a m a t i c
increase in MTX and 7OH-MTX concentrations are found
in the liver, as well as prolonged systemic exposure to both
compounds after MTX administration compared to single
gene knockout mice [59]. There is currently a knowledge
deﬁcit regarding the ontogeny of these transporters. If
dysfunction in eﬄux transporters such as ABCC2, ABCC3,
and ABCG2 leads to prolonged systemic exposure and
elevated liver concentrations of MTX, perhaps more eﬀective
or eﬃcient function of these transporters in children allow
high doses to be tolerated and hepatic toxicity to be minimal.
The complexity involved in predicting the cellular eﬀects
of MTX is only ampliﬁed by the multiple steps required
to complete the journey to the cellular folate cycle, and
recognizing that cell- and tissue-speciﬁc diﬀerences in
cellular uptake and retention processes exist. The role of
ontogeny adds a layer of complexity to an already intricate
network of genes. Very little is known about diﬀerences
in gene expression with age within the network during
normalgrowthanddevelopment,letaloneafterperturbation
following administration of MTX. Extensive variability in
outcomes and intracellular MTXglun concentrations in our
pediatric JIA population, as well as the observation that
children need and tolerate the same absolute doses of the
drug routinely prescribed to adults, begs the question: what
role does ontogeny play?
8. Conclusions
Although MTX is widely used in clinical practice—in a
number of disease entities, at diﬀerent doses and by diﬀerent
routes of administration—there remains signiﬁcant lack of
understanding of its mechanisms of action and the factors
thatcontributetothevariabilityintoxicityandresponseseen
clinically. Given the time lag between initiation of treatment
and the ﬁrst indication of patient response, this knowledge is
essential to determine ap r i o r ithe probability of beneﬁcial
therapeutic response and also take into consideration the
probability of toxicity so that the best informed clinical
decisions can be made. In addition to diﬀerences in drug
administration, (i.e., dose, route, compliance) factors that
aﬀect pharmacokinetics and pharamcodynamics such as
genetic variation may explain individual diﬀerences in drug
biotransformation. However, the pediatric population has
an additional factor to consider, namely, the ontogeny of
gene expression, which may invariably aﬀect the relative
expression of genes within the pathway as one carbon
resources which are allocated to the diﬀerent functions of
the folate cycle (purine and pyrimidine biosynthesis, homo-
cysteine remethylation to methionine, one carbon donor for
methyltransferases) during periods of dynamic change in
folate supply and demand. By taking into account not only
the genes in question that may aﬀect drug disposition, but
also the developmental trajectory of genes involved in drug
response, we may begin to better understand what makes
children diﬀerent, and identify and prevent unique adverse
drug reactions in this population. Future areas of study
in this area may include investigating the developmental
expressionoftissuespeciﬁctransporters,whichmayexplain-
ing the higher rate of subcutaneous administration and the
higher doses of MTX used in children compared to adults.
Additionally, having a better understanding of how cellular
folate concentrations and patterns change with age may also
helpexplainthevariationseeninMTXresponse.Withnewer
techniquesandadevelopmentallyawareapproach,weaimto
successfully individualize therapy for our pediatric patients
with JIA.
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